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Abstract
Background: One of two proapoptotic Bcl-2 proteins, Bak or Bax, is required to permeabilize the mitochondrial outer
membrane during apoptosis. While Bax is mostly cytosolic and translocates to mitochondria following an apoptotic
stimulus, Bak is constitutively integrated within the outer membrane. Membrane anchorage occurs via a C-terminal
transmembrane domain that has been studied in Bax but not in Bak, therefore what governs their distinct subcellular
distribution is uncertain. In addition, whether the distinct subcellular distributions of Bak and Bax contributes to their
differential regulation during apoptosis remains unclear.
Methodology/Principal Findings: To gain insight into Bak and Bax targeting to mitochondria, elements of the Bak C-
terminus were mutated, or swapped with those of Bax. Truncation of the C-terminal six residues (C-segment) or substitution
of three basic residues within the C-segment destabilized Bak. Replacing the Bak C-segment with that from Bax rescued
stability and function, but unexpectedly resulted in a semi-cytosolic protein, termed Bak/BaxCS. When in the cytosol, both
Bax and Bak/BaxCS sequestered their hydrophobic transmembrane domains in their hydrophobic surface groove. Upon
apoptotic signalling, Bak/BaxCS translocated to the mitochondrial outer membrane, inserted its transmembrane domain,
oligomerized, and released cytochrome c. Despite this Bax-like subcellular distribution, Bak/BaxCS retained Bak-like
regulation following targeting of Mcl-1.
Conclusions/Significance: Residues in the C-segment of Bak and of Bax contribute to their distinct subcellular localizations.
That a semi-cytosolic form of Bak, Bak/BaxCS, could translocate to mitochondria and release cytochrome c indicates that Bak
and Bax share a conserved mode of activation. In addition, the differential regulation of Bak and Bax by Mcl-1 is
predominantly independent of the initial subcellular localizations of Bak and Bax.
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Introduction
The intrinsic or mitochondrial pathway of apoptosis is regulated by
the Bcl-2 protein family, with two members, Bak and Bax, required to
permeabilize the mitochondrial outer membrane (OM) [1,2]. During
OM permeabilization, Bak and Bax undergo significant conforma-
tion change involving exposure of N-terminal epitopes and homo-
oligomerization [3,4,5,6,7] to form an as yet undefined pore. Bak
conformation change also involves transient exposure of the BH3
domain that then binds to the hydrophobic groove of another
activated Bak molecule to form symmetric dimers [8,9,10], with the
sameprocess alsoevident for Bax [11,12,13,14]. Symmetric dimers of
Bak and of Bax can then be linked by an a6:a6 interface into higher
order oligomers that likely constitute the apoptotic pore [8,12].
Bak and Bax are regulated by other Bcl-2 family members.
They are activated by direct binding of BH3-only proteins (e.g.
Bim and tBid), and sequestered by binding to prosurvival proteins
(e.g. Mcl-1 and Bcl-2) [15,16,17,18,19,20]. Specific binding results
in Bak being guarded mainly by Bcl-xL, Mcl-1 and A1, while Bax
is countered mainly by Bcl-2, Bcl-xL, Bcl-w and A1 [20,21,22,23].
This specific binding can result in either Bak or Bax preferentially
driving apoptosis [24,25]. For example, Bak-driven apoptosis can
be initiated by loss of the relatively labile Mcl-1 and Bcl-xL
following UV, actinomycin D or cycloheximide [20,26].
Bak and Bax contain a C-terminal hydrophobic region that
inserts as a transmembrane (TM) domain into the mitochondrial
OM. The C-termini of Bak and Bax can target GFP to
mitochondria [27,28], and their truncation in the native proteins
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[27,28,29,30,31]. Two or more basic residues in the extreme C-
terminus (i.e. within the C-segment) may assist insertion of the TM
domain across the OM, as observed for other mitochondrial tail-
anchored proteins [30,32,33]. Whether the TM domain inserts
spontaneously across the mitochondrial membrane remains con-
troversial [27,28], however peptides equivalent to the C-termini of
Bak (24 residues) and of Bax (24 residues) can integrate into model
membranes in the absence of chaperones or receptors [34,35].
Bak is integrated in the OM in healthy cells, whereas Bax is
largely cytosolic until its translocation to mitochondria after
apoptotic signalling [36]. A portion of Bax that is peripherally
attached to mitochondria in healthy cells can retrotranslocate upon
binding Bcl-xL [37]. Cytosolic Bax is proposed to sequester its TM
domain in a hydrophobic surface groove through an interaction
involving hydrogen bonding between S184 in the TM domain and
D98 in the groove [30,38]. While others have examined how the C-
termini of Bax, Bcl-xL, and Bcl-2 control mitochondrial targeting
[30,31,39,40], this has not been examined for Bak.
To understand how Bak is targeted to mitochondria, and to
address whether differences in Bak and Bax localization might
contribute to their differential regulation, we mutated the C-
terminus of Bak. Removing the C-segment (C-terminal six
residues), or the basic residues within, decreased mitochondrial
targeting and protein stability, thereby decreasing proapoptotic
function. Notably, replacing the C-segment of Bak with that from
Bax converted Bak to a relatively stable, semi-cytosolic protein
(named Bak/BaxCS) that could translocate to mitochondria.
Translocation of both Bak/BaxCS and Bax following apoptotic
signalling suggests similar activation mechanisms for Bak and Bax.
Furthermore, the semi-cytosolic localization of Bak/BaxCS did
not alter its regulation by Mcl-1.
Results
The Bak C-segment is required for stability, mitochondrial
targeting and proapoptotic function
To identify elements in the Bak C-terminus that are required for
OM targeting and integration, the whole C-terminus or just the C-
segment was truncated (BakDCT, BakDCS; Figure 1A). Following
stable expression in bak
2/2bax
2/2 MEFs, both truncated proteins
failed to mediate cytochrome c release and apoptosis after
exposure to UV or etoposide (Figure 1B and Figure S1). BakDCT
was relatively stable, as protein expression levels were very high,
and half-life as assessed by incubation in cycloheximide was similar
to that of Bak (Figures 1B and C). In contrast, BakDCS was
unstable as indicated by low expression level, low half-life, and
degradation following UV treatment (Figures 1B, C, D), perhaps
due to an exposed TM domain targeting the protein for
degradation. The truncated proteins were inefficient at targeting
membranes both before and after apoptotic signalling (Figures 1D
and E). In Bax, truncation of the C-terminus (23 residues) or C-
segment (
188WKKMG
192) also blocked mitochondrial transloca-
tion and function (data not shown), as reported previously
[27,30,31]. Thus, the C-termini, including the C-segments, are
required for targeting stably expressed Bak and Bax to
mitochondria.
Notably, the Bak C-terminus was also necessary for apoptotic
conformation change and oligomerization, as BakDCT essentially
remained in the non-activated conformation, and failed to
dimerize following UV treatment (Figure 1E). Moreover, BakDCT
failed to change conformation following addition of the proapop-
totic BH3-only protein tBid to cell extracts [8].
Basic residues in the Bak C-segment govern stability and
function
Basic residues in the C-segment of tail-anchored proteins can
assist in membrane-integration and in targeting specific mem-
branes [30,32,33]. To examine the role of the three basic residues
in the Bak C-segment, one, two, or all three, were replaced with
serine (Figure 2A). Substitution of all three basic residues (BakSSS)
had a similar effect to C-segment truncation, as the protein was
unstable as shown by low expression level and low half-life, with
cytochrome c release and apoptosis greatly decreased (Figures 2B
and C and Figure S1). Substitution of the last two basic residues
(BakRSS) slightly blocked apoptotic function (Figure 2B and
Figure S1) despite high protein levels (Figure 2B) and efficient
membrane targeting (Figure 2D). This diminished function of
BakRSS may be due to targeting to non-mitochondrial mem-
branes, as reported for Bcl-xL when either basic residue in the C-
segment was replaced [39], although attempts to examine this by
both cell fractionation and confocal microscopy were not
conclusive (data not shown). Finally, substitution of a single basic
residue at two positions had little effect on localization or apoptotic
function (BakRRS, BakSRK; Figures 2B and D and data not
shown). While we have not tested whether the second or third
basic residue alone (e.g. BakSRS or BakSSR) may efficiently target
Bak to mitochondria, our data suggest that two basic residues in
the Bak C-segment are necessary for efficient proapoptotic
function, as shown for Bcl-xL [39]. However, a third basic residue
may contribute to Bak stability, as BakRRS had a slightly lower
half-life compared to Bak, and many vertebrate Bak proteins
contain three basic residues in the C-segment.
Substitution of the Bak C-segment with that of Bax
preserves Bak stability and function, but confers cytosolic
localization
Toexplore the roleofthe C-terminiinthedifferentiallocalization
ofBakandBaxwegeneratedthreechimerasinwhichthewholeBak
C-terminus,orjust the TMdomainorC-segment was replacedwith
that of Bax (Figure 3A). Bak containing the Bax C-terminus (Bak/
BaxCT) exhibited the characteristics of wild-type Bak in terms of
expression level, half-life, mitochondrial localization, oligomeriza-
tion and proapoptotic function (Figures 3B, C, D, E, F, G and
Figure S1). Thus, the Bax C-terminus could act as a fully functional
membrane anchor for Bak. The protein was fully membrane-bound
prior to apoptosis, presumably due to inability of the Bax TM
domain to be sequestered in the Bak groove.
Bak containing the Bax TM domain (Bak/BaxTM) was
relatively unstable. The protein displayed reduced proapoptotic
function, short half-life, and rapid degradation following UV
(Figures 3B, C, D, E and Figure S1). This chimera also exhibited
impaired targeting to membranes (Figures 3D and E), suggesting
that the secondary structure of the ‘‘mixed’’ C-terminus may not
be optimal for membrane insertion. As the membrane-integrated
population was also unstable (Figures 3D and E), the Bak C-
terminus may not only be important for targeting and insertion,
but also for stability of the protein once membrane anchored.
Notably, Bak containing the Bax C-segment (Bak/BaxCS) was
fully functional in mediating apoptosis, as indicated by cytochrome
c release and by loss of cell viability in a caspase-dependent
manner (Figure 3B and Figures S1 and S2). Accordingly, the
protein exhibited normal half-life (Figure 3C). However, instead of
being located solely in the mitochondrial fraction, a significant
portion of the protein was now cytosolic in healthy cells
(Figures 3D and E). The portion of Bak/BaxCS that did locate
to mitochondria was partially inserted as indicated by carbonate
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BaxCS still underwent conformation change and oligomerization
following UV (Figures 3F and G) or actinomycin D (Figure S3),
with oligomerization predominantly in the membrane fraction. A
variant of this chimera that contains five (WKKMG) rather than
four (KKMG) Bax residues displayed similar subcellular localiza-
tion and proapoptotic function (Bak/BaxCS
b; Figure S4 and data
not shown). In summary, Bak/BaxCS remained functional despite
significant initial cytosolic localization.
To examine in more detail whether the cytosolic fraction of
Bak/BaxCS can translocate and permeabilize mitochondria, a
series of experiments were performed. Subcellular fractionation
showed that after treatment with apoptotic stimlui, Bak/BaxCS is
predominantly at mitochondria (Figures 3D, E and G and Figure
S3), although partial loss of Bak/BaxCS following UV treatment
precluded clear conclusions regarding translocation (e.g.
Figures 3D and E). By confocal microscopy, Bak/BaxCS (tagged
with FLAG at the N-terminus) also increased at mitochondria in a
portion of cells after treatment with etoposide (Figure S5),
although translocation was not marked due to the portion of
Bak/BaxCS already resident at mitochondria. We then tested
translocation and permeabilization in cell-free assays by combin-
ing Bak/BaxCS cytosolic extracts with mitochondria from two
different sources (Figure 4). When MEF cytosol containing Bak/
BaxCS was ‘‘recombined’’ with MEF membranes containing Bak/
BaxCS, the addition of tBid triggered cytochrome c release
(Figure 4A, lanes 2 and 3). However, cytochrome c was not
released if either fraction was combined with cytosol or
Figure 1. The Bak C-segment is essential for stability, membrane targeting and proapoptotic function. (A) C-terminal sequence of Bak
variants truncated at the C-terminus. The C-terminus (CT) contains a hydrophobic transmembrane (TM) domain and a hydrophilic C-segment (CS). (B)
Truncation of the Bak C-terminus or C-segment blocks proapoptotic function. bak
2/2bax
2/2MEFs expressing Bak, BakDCT and BakDCS were left
untreated, or treated with UV or etoposide for 24 h. Percentage cell death is expressed as the mean 6 SEM from three independent experiments.
Statistical significance for treatment when compared to Bak; ***p,0.001. Upper panel is a western blot of cell lysates immunoblotted for Bak, and for
b-actin as a loading control. (C) Truncation of the C-segment reduces half-life. Cells from (B) were incubated with cycloheximide for up to 24 h and
cell lysates immunoblotted for Bak, and for b-actin as a loading control. Note that due to low expression of BakDCS, 4-fold total protein was loaded
onto the gels. (D) Truncation of the Bak C-terminus prevents membrane targeting. Cells were left untreated or treated with UV, separated into
cytosolic and membrane fractions, and immunoblotted for Bak and the cytosolic marker HSP70. (E) Bak lacking the C-terminus fails to undergo
conformation change and oligomerization in response to UV. Cells treated as in (D) were exposed to oxidant (CuPhe), separated into cytosolic and
membrane fractions, run on non-reducing SDS-PAGE and immunoblotted for Bak. MX, non-activated intramolecular cross-linked monomer; M, non-
crosslinked monomer; D, intermolecular crosslinked dimers. Results are representative of two or more independent experiments.
doi:10.1371/journal.pone.0031510.g001
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2/2bax
2/2 MEF (Figure 4A, lanes 6,7, 10
and 11), indicating that both the cytosolic and mitochondrial
portions of Bak/BaxCS are required to reach the threshold of Bak
necessary for cytochrome c release in this assay. Blotting for Bak
indicated that this threshold (lanes 2 and 3) includes resident
mitochondrial Bak/BaxCS (e.g. lane 5) as well as cytosolic Bak/
BaxCS recruited to mitochondria in the absence of tBid (e.g. lane
9) and in the presence of tBid (e.g. lane 10).
In a second cell-free assay (Figure 4B), MEF cytosol fractions were
incubated with mouse liver mitochondria which contain very low
levels of Bcl-xL and Mcl-1 [41]. Cytosolic Bak/BaxCS was now able
tomediatecomplete cytochromecreleasebytBid(Figure4B,lane 4).
Again, a portion ofBak/BaxCSwasrecruited to mitochondria inthe
absence of tBid, with further protein recruited during tBid
incubation (lanes 3 and 4). While the recruited Bak/BaxCS (lanes
3 and 4) appears greater than the resident mouse Bak in bak
+/+ liver
mitochondria (lanes 5 and 6), the anti-Bak antibody was raised
against a peptide derived from the human 23–38 sequence that
differs from that of mouse Bak. Notably, in this assay the cytosolic
Bak/BaxCS protein was solely responsible for cytochrome c release
as liver mitochondria from bak
2/2 mice are essentially devoid of Bak
and Bax [41]. A direct comparison of Mcl-1 levels in the two sources
of mitochondria (Figure 4C) suggests that a low Mcl-1 level in mouse
liver mitochondria confers a low threshold of Bak required for
cytochrome c release. In summary, in these cell-free assays, cytosolic
Bak/BaxCS could translocate to the mitochondrial fraction, and
contribute to cytochrome c release initiated by tBid (Figure 4). These
findings, together with evidence of translocation following apoptotic
signalling in cells (Figure 3 and Figures S3 and S5), indicate that in
cells undergoing apoptosis (Figure 3), both the cytosolic and
mitochondrial fractions of Bak/BaxCS are functional.
A TM: Groove interaction contributes to the cytosolic
localization of Bax and Bak/BaxCS
As discussed above, structure and mutagenesis studies found
that cytosolic Bax is stabilized by a TM:groove interaction possibly
involving hydrogen bonding between S184 (TM) and D98 (groove)
Figure 2. Basic residues in the C-segment are necessary for Bak stability and function. (A) C-terminal sequence of Bak variants indicating
which basic residues in the C-segment that were substituted with serine. (B) Substitution of basic residues in the C-segment reduces Bak
proapoptotic function. bak
2/2bax
2/2 MEFs expressing Bak, BakRRS, BakRSS or BakSSS were left untreated, or treated with UV or etoposide for 24 h.
Percentage cell death is expressed as the mean 6 SEM from three independent experiments. Statistical significance for treatment when compared to
Bak; *p,0.05, **p,0.01. Upper panel is a western blot of cell lysates immunoblotted for Bak, and for b-actin as a loading control. (C) Substitution of
basic residues in the C-segment destabilizes Bak. Cells from (B) were incubated with cycloheximide for up to 24 h and cell lysates immunoblotted for
Bak, and for b-actin as a loading control. Note that due to low expression of BakSSS, 4-fold total protein was loaded onto the gels. (D) Substitution of
basic residues does not prevent targeting to membranes. Cells from (B) were left untreated or treated with UV, separated into cytosolic and
membrane fractions, and immunoblotted for Bak and for the cytosolic marker HSP70. Results are representative of two or more independent
experiments.
doi:10.1371/journal.pone.0031510.g002
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Bax C-terminus or C-segment retains stability and function. bak
2/2bax
2/2MEFs expressing Bak or Bak/Bax chimeras were left untreated or treated
with UV or etoposide. Percentage cell death is expressed as the mean 6 SEM from three independent experiments. Statistical significance for
treatment when compared to Bak; **p,0.01. Upper panel is a western blot of cell lysates immunoblotted for Bak and for b-actin as a loading control.
(C) Bak containing the Bax C-terminus or C-segment retains stability. Cells from (B) were incubated with cycloheximide and cell lysates
immunoblotted for Bak, and for b-actin as a loading control. (D) Bak containing the Bax transmembrane domain or C-segment locates to both
cytosolic and membrane fractions. Cells from (B) were left untreated or treated with UV, separated into cytosolic and membrane fractions and
immunoblotted for Bak or Bax, and for the cytosolic marker HSP70. (E) Bak/Bax chimeras in the membrane fraction are mostly membrane-integrated.
Cells were treated as in (D) and the membrane fractions treated with sodium carbonate to extract peripherally attached proteins. Samples were
immunoblotted for Bak or Bax. (F) Bak/Bax chimeras retain ability to change conformation and oligomerize during apoptosis. Cells were treated as in
(D) and the cell lysates exposed to oxidant (CuPhe), run on non-reducing SDS-PAGE, and immunoblotted for Bak. MX, non-activated intramolecular
crosslinked monomer; M, non-crosslinked monomer; D, intermolecular crosslinked dimers; T, crosslinked trimers. (G) Following UV, oligomerized Bak/
BaxCS is mainly at mitochondria. Cells were treated as in (D), separated into cytosolic and membrane fractions, run on non-reducing SDS-PAGE and
immunoblotted for Bak. Results are representative of two or more independent experiments.
doi:10.1371/journal.pone.0031510.g003
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linkage to examine whether the cytosolic populations of Bax and
Bak/BaxCS adopt a TM:groove interaction. We first substituted
the two endogenous cysteines in Bax (C62 and C126) and in Bak/
BaxCS (C14 and C166) for serine. Then cysteine residues were
placed in the TM and groove at positions predicted to interact in
Bax (D98C/S184C), and at equivalent positions in Bak/BaxCS
(S117C/Q202C). As controls, single cysteine substitutions in Bax
(D98C and S184C) and Bak/BaxCS (S117C and Q202C) were also
examined. Each Bax and Bak/BaxCS cysteine variant retained
proapoptotic function when stably expressed in bak
2/2bax
2/2MEFs
(Figure S6 and unpublished data).
We first noted that subcellular localization was altered by the
cysteine substitutions, as cysteine in the TM of both Bax (S184C)
and Bak/BaxCS (Q202C) increased localization to the membrane
fraction (Figure 5B, lanes 4). As cysteine is more hydrophobic than
serine or glutamine, it may encourage membrane insertion, as
previously reported for Bax in which S184 was substituted with a
more hydrophobic residue (BaxS184V, S184A and S184L) [30,44].
To then test whether cysteines in the TM and groove were in
close proximity in cytosolic Bax and Bak/BaxCS, we tested
whether the two cysteines could form an intramolecular disulphide
bond after addition of the oxidant, copper (I,II) phenanthroline
(CuPhe). As predicted by the Bax structure, intramolecular
Figure 4. Bak/BaxCS translocates to mitochondria and following tBid releases cytochrome c. (A) Cytosolic and mitochondrial Bak/BaxCS
both contribute to permeabilization of MEF mitochondria. Cytosol and membrane fractions from bak
2/2bax
2/2 MEFs or from bak
2/2bax
2/2 MEFs
expressing either Bak or Bak/BaxCS were combined as shown, and incubated at 30uC in the presence of 100 nM tBid for 0, 30 or 60 mins, or without
tBid for 60 mins (60-). Supernatant (Cyt) and membrane (Memb) fractions were immunoblotted for cytochrome c and for Bak. (B) Cytosolic Bak/BaxCS
is sufficient to permeabilize mouse liver mitochondria. MEF cytosol fractions derived as in (A) were combined with mitochondria isolated from wild-
type (bak
+/+)o rbak
2/2 mouse liver, and incubated at 37uC with or without 100 nM tBid for 60 min. Supernatant (Cyt) and membrane (Memb)
fractions were immunoblotted for cytochrome c and for Bak. Note that Bak/BaxCS levels appear high compared to the endogenous mouse Bak,
possibly due to different recognition by the anti-Bak antibody. (C) Mcl-1 is higher in MEF membranes than in mouse liver mitochondria. MEF
membranes and mouse liver mitochondria at the concentrations used in (A) and (B) were examined for levels of Mcl-1, Bcl-xL and VDAC1 by
immunoblotting. Results are representative of two or more independent experiments.
doi:10.1371/journal.pone.0031510.g004
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e31510Figure 5. A TM:groove interaction forms in cytosolic Bax and in cytosolic Bak/BaxCS. (A) Schematic of Bax converting from a TM:groove
to a TM:membrane conformation during apoptosis. Bax is shown as surface representation (orange) with the hydrophobic surface groove highlighted
(white). The Bax TM domain is represented (blue) and the C-segment (KKMG) has the sidechains shown. Residues proposed to interact during
TM:groove interaction are highlighted (S184 and D98; red). Images were generated in Pymol using the RCSB Protein Data Bank file 1F16 for Bax [38].
(B) Mutations in both the TM domain and the groove alter mitochondrial targeting. Cytosolic and membrane fractions from bak
2/2bax
2/2 MEFs
expressing the indicated Bax or Bak/BaxCS cysteine mutants were immunoblotted for Bax, Bak/BaxCS, or HSP70. (C) A TM:groove interaction forms in
cytosolic Bax and in cytosolic Bak/BaxCS. Cytosolic and membrane fractions from cells in (B) were incubated with oxidant (CuPhe) and
electrophoresed under non-reducing conditions (upper) or reducing conditions (+2ME, lower) and immunoblotted for Bax or Bak/BaxCS.
Intramolecular cysteine linkage (D98C:S184C in Bax; S117C:Q202C in Bak/BaxCS) results in faster migration under non-reducing conditions (X-link). (D)
Etoposide treatment decreases TM:groove interaction in membrane-associated Bak/BaxCS. Cells expressing the Bak/BaxCS S117C/Q202C variant were
incubated with or without etoposide for 24 h. Cytosolic and membrane fractions were incubated with CuPhe, electrophoresed under non-reducing
conditions, and immunoblotted for Bak. (E) tBid treatment decreases the TM:groove interaction in membrane-associated Bak/BaxCS. Cells in (D) were
permeabilized and incubated with or without tBid (100 nM). Cytosolic and membrane fractions were separated and then incubated with CuPhe,
electrophoresed under non-reducing conditions, and immunoblotted for Bak. (F) The TM domain of Bak/BaxCS inserts into membranes following
tBid. Permeabilized cells were treated with or without tBid as in (E), then incubated with or without IASD. Membrane fractions were electrophoresed
under reducing conditions and immunoblotted for Bak. Results are representative of two or more independent experiments.
doi:10.1371/journal.pone.0031510.g005
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(D98C/S184C) in the cytosolic fraction, as under non-reducing
conditions (CuPhe) the protein migrated further than the single-
cysteine variants (Figure 5C, compare lane 5 to lanes 1–4).
Cysteine linkage was also apparent for the double-cysteine variant
of Bak/BaxCS (S117C/Q202C) compared to the single-cysteine
variants (Figure 5C, compare lane 5 with lanes 1–4). Disulphide
linkage was responsible for the fast migration as the reducing agent
2-mercaptoethanol (2ME) prevented faster migration for both
double-cysteine variants (Figure 5C, lower gels, lanes 5). Cysteine
linkage was not evident in the membrane fractions of the double-
cysteine variants, likely due to membrane insertion of the TM
domain (Figure 5C, lanes 6). In summary, a TM:groove
interaction was evident both in cytosolic Bax and in cytosolic
Bak/BaxCS.
We next examined whether Bak/BaxCS and Bax convert from
a TM:groove conformation to a TM:membrane conformation
during apoptosis, as depicted for Bax in Figure 5A. Cells
expressing the double-cysteine Bak/BaxCS variant (S117C/
Q202C) were treated with etoposide to induce apoptosis, and
the cell fractions treated with CuPhe and examined for TM:groove
linkage (X-link; Figure 5D). Here, TM:groove linkage was evident
not only in the cytosolic fraction but in part of the membrane-
associated protein prior to etoposide, presumably due to some
Bak/BaxCS being peripherally attached to mitochondria, as
indicated by carbonate extraction (Figure 3E) and by partial
dissociation from membranes during a 30 min incubation in bak
2/
2bax
2/2 MEF cytosol (Figure 4A, lanes 5–8). Notably however,
TM:groove linkage in the membrane fraction decreased after
etoposide (Figure 5D, compare lanes 2 and 4). (Unfortunately,
several experiments with the double-cysteine Bax variant could not
clearly distinguish a decrease in TM:groove linkage.) In a second
approach, cell extracts from these cells were incubated with tBid
(as in Figure 4A), and cytosol and membrane fractions subjected to
oxidation and examined for TM:groove linkage (X-link;
Figure 5E). tBid caused the double-cysteine Bak/BaxCS variant
to translocate to the membrane fraction, and decreased the
proportion of protein that could undergo TM:groove linkage
(Figure 5E). The observed decrease in the TM:groove conforma-
tion of Bak/BaxCS after either etoposide or tBid is consistent with
insertion of the TM domain (that contains the Cys202 residue) into
the mitochondrial OM.
To more directly monitor membrane insertion of the Bak/
BaxCS TM domain, a cysteine labelling approach was used
(Figure 5F). Cysteine can be labelled irreversibly by 4-acetamido-
49-((iodoacetyl) amino) stilbene-2,29-disulfonic acid (IASD), except
if the cysteine is positioned in hydrophobic environments such as
lipid bilayers [45]. Cysteine was thus introduced at position V194
in the TM domain of Bak/BaxCS, and the protein found to retain
proapoptotic function (data not shown). Cell lysates were then
incubated with or without tBid and subjected to IASD-labelling.
Bak/BakCS in membrane fractions showed an increase in
molecular weight conferred by the IASD molecule (624 Da).
While most of the membrane-associated V194C could be labelled
before tBid, labelling decreased after tBid (Figure 5F). Thus,
cysteine linkage and cysteine labelling both indicate that Bak/
BaxCS translocation to mitochondria during apoptosis involves
conversion from a TM:groove to a TM:membrane conformation,
as depicted for Bax in Figure 5A.
Regulation of Bak and Bax is independent of initial
subcellular localization
How Bak and Bax are regulated by prosurvival Bcl-2 proteins is
a major enigma in the field. Having shown that Bak/BaxCS is
semi-cytosolic and that the cytosolic portion of Bak/BaxCS was
important for cell death in these cells, we examined whether
subcellular localization contributes to the differential regulation of
Bak and Bax. For example, do apoptotic signals that preferentially
initiate Bak-dependent apoptosis, also initiate Bak/BaxCS-depen-
dent apoptosis? To test this we used a retroviral approach to
express three BimS variants in MEFs that already stably express
different Bak and Bax variants. The three BimS variants were wild
type BimS, or BimS in which the BH3 domain was swapped with
the BH3 domain of Bad (BimS
BAD) or of Noxa (BimS
NOXA). The
predicted effects of each BimS variant is described in the schematic
in Figure 6A, which depicts Mcl-1 as the principal guardian of Bak
Figure 6. Bak regulation is independent of initial subcellular
localization. (A) Schematic of Bak-mediated apoptosis initiated by
Noxa-Mcl-1 signalling in MEFs. The four prosurvival proteins expressed
in MEF (Mcl-1, Bcl-xL, Bcl-w and Bcl-2) are depicted, together with their
preferential binding of BH3-only proteins (Noxa, Bim and Bad) and of
Bak and Bax [20,46]. The Noxa-Mcl-1-Bak pathway to apoptosis is
indicated (bold). (B) Expression of BimS
NOXA preferentially mediates
apoptosis via either Bak or Bak/BaxCS. bak
2/2bax
2/2MEFs expressing
the indicated Bak and Bax variants were retrovirally infected with BimS
or with BimS containing the Bad or Noxa BH3 domains (BimS
BAD and
BimS
NOXA). Percentage cell death at 36 h (normalized to the efficiency of
infection) is expressed as the mean 6 SEM of three independent
experiments. Statistical significance for treatment when compared to
Bak; **p,0.01.
doi:10.1371/journal.pone.0031510.g006
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Noxa, Bim and Bad to prosurvival proteins, and the binding
profiles of prosurvival proteins to Bak and Bax [18,19,20,46].
We used bak
2/2bax
2/2MEFs that had been stably transfected
with Bak, Bak/BaxCS, Bax or a mitochondria-targeted BaxS184L
variant [44]. In each of these cells lines, expression of BimS
initiated apoptosis (Figure 6B), explained by strong binding of
BimS to all prosurvival proteins (and perhaps direct activation of
both Bak and Bax by BimS). In contrast, expression of BimS
BAD
failed to induce apoptosis in any cell line, explained by weak
binding of Bad to Mcl-1. Notably, BimS
NOXA efficiently initiated
apoptosis in cells expressing Bak because Noxa binds strongly to
Mcl-1 to leave Bak unguarded. In contrast, BimS
NOXA did not kill
cells expressing Bax because Noxa does not bind to three Bax
guardians (Bcl-2, Bcl-w and Bcl-xL). Thus, this approach
distinguishes between Bak- and Bax-mediated apoptosis. We then
noted that BimS
NOXA was still able to initiate cell death via Bak/
BaxCS as efficiently as via wild-type Bak, indicating that the semi-
cytosolic locale of Bak/BaxCS did not alter its regulation.
We note that in these experiments, Noxa expression alone was
sufficient to kill bak
2/2bax
2/2 MEFs expressing human Bak,
presumably because Mcl-1 is the principal guardian of Bak in
these cells and because Noxa can directly activate Bak [47]. This
contrasts with earlier studies in which Noxa required co-expression
of Bad to kill bax
2/2MEFs [46]. One possibility is that in the
present studies, enforced expression of hBak has altered the profile
of prosurvival proteins to make Mcl-1 dominant. Consistent with
this, altering the prosurvival profile by overexpressing Bcl-xL made
the cells resistant to Noxa-induced killing (Figure S7).
Bak and Bax regulation in these cells was also tested by initiating
apoptosis with UV, cycloheximide and actinomycin D, three
agents that are thought to initiate Bak-dependent apoptosis by
degrading Mcl-1 and/or by increasing Noxa expression
[20,26,48]. Accordingly, these stimuli preferentially triggered
apoptosis via Bak or Bak/BaxCS, whereas etoposide induced
apoptosis equally via Bak, Bak/BaxCS or Bax (Figure S8). The
major role of Mcl-1 in regulating Bak and Bak/BaxCS in these
cells is supported by experiments in which both Bak and Bak/
BaxCS readily co-precipitated with Mcl-1, while Bax and
BaxS184L did so only poorly (Figure S9). Thus, Bak-mediated
apoptosis initiated by targeting Mcl-1 is independent of the initial
intracellular localization of Bak.
Discussion
The Bak transmembrane domain and C-segment both
contribute to mitochondrial targeting and membrane
insertion
The C-termini of tail-anchored proteins, including Bak and
Bax, contain an a-helical transmembrane domain often flanked by
basic residues [32,33]. Accordingly, in Bak, truncation of the
whole C-terminus (25 residues) rendered Bak cytosolic and non-
functional when stably expressed in bak
2/2bax
2/2 MEFs (Figure 1)
[29], as reported for transient transfection of HeLa cells [28].
Likewise, truncation of the Bax C-terminal 23 residues also
blocked its function in bak
2/2bax
2/2MEFs (data not shown), as
recently shown for Bax with GFP fused to the C-terminus [31].
Truncation of just the C-segment also rendered Bak largely
cytosolic and non-functional, as reported for truncation of the C-
segment of Bax [30]. Substitution of the three basic residues in the
Bak C-segment also significantly decreased half-life and function.
Thus, our results based on stable expression of Bak and Bax in
Bak/Bax-deficient cells verify that the C-terminus of each protein
is necessary for targeting and insertion into the mitochondrial
outer membrane, and show that the C-segment within these
regions plays a vital role. Somewhat curiously, the C-terminus, or
C-terminus-dependent mitochondrial localization, was also need-
ed for Bak activation and conformation change, as truncation of
the C-terminus essentially prevented Bak conformation change in
response to tBid or UV (Figure 1E) [8].
Bak/BaxCS, a semi-cytosolic functional form of Bak
A semi-cytosolic form of Bak, Bak/BaxCS, was generated by
replacing the Bak C-segment (RRFFKS) with that of Bax (KKMG).
This chimera retained proapoptotic function despite its significant
distributioninthe cytosol, suggestingthat itmaytranslocate like Bax
to mitochondria and permeabilize the OM. Indeed, translocation of
the cytosolic portion to mitochondria was observed in cell-free
assays and in cells. Notably, recruitment of cytosolic Bak/Bax to
MEF mitochondria was necessary to reach the threshold of
mitochondrial Bak needed for OM permeabilization in cell-free
assays, suggesting that Bak/BaxCS translocation is also necessary
for OM permeabilization in intact MEF cells. The ability of
cytosolic Bak/BaxCS and of cytosolic Bax to translocate to
mitochondria, oligomerize and permeabilize the OM during
apoptosis suggests a conserved mode of activation for Bak and Bax.
In the cytosol, Bak/BaxCS was able to sequester the
hydrophobic TM domain in the hydrophobic surface groove, as
shown by cysteine linkage. A similar TM:groove interaction in
cytosolic Bax was also evident, as proposed by structural and
mutagenesis studies [42,43]. A TM:groove interaction was less
evident in mitochondrial Bak/BaxCS, especially following apo-
ptotic signalling, indicating that the TM domain moves from the
hydrophobic groove to insert into the hydrophobic OM. Actual
insertion into the OM following tBid was indicated by decreased
labelling of cysteine introduced into the TM domain of Bak/
BaxCS.
A TM:groove interaction in cytosolic Bak/BaxCS also implies
that although the Bak groove appears ‘‘closed’’ in the structure of
non-activated Bak [49], it may ‘‘open’’ to accommodate the TM
domain while remaining non-activated. Thus, plasticity evident in
the hydrophobic grooves of the prosurvival proteins Bcl-xL and A1
[50] may extend to the hydrophobic groove in Bak. Indeed, a
recent study showed that the Bak groove could transiently bind
activator BH3-only proteins, initiating Bak activation [47]. A
much greater change in the groove is presumably involved in Bak
activation, where the groove opens to expose the BH3 domain and
then bind the BH3 domain of another activated Bak molecule,
resulting in symmetric dimers [8,29].
How the Bax C-segment in Bak/BaxCS promotes a TM:groove
interaction is not clear. It is possible that the Bax C-segment
(KKMG) forms opportunistic interactions with negatively charged
residues on the groove surface (e.g. E105 and E109 in Bak a-helix
4), which then stabilize TM binding to the body of the protein.
Alternatively, the hybrid of Bak TM domain with Bax C-segment
may hinder membrane insertion, and so skew Bak/BaxCS towards
a TM:groove interaction in the cytosol. It is unlikely that the Bax
C-segment acts by altering Bak/BaxCS binding to proteins in the
cytosol or mitochondria, as cells sorted for low or high levels of
Bak/BaxCS exhibited a similar distribution of cytosolic vs
mitochondrial Bak/BaxCS (data not shown).
The role of the C-terminus in Bak stability and
conformation
Certain changes to the Bak C-termini decreased protein stability
or altered conformation, highlighting the importance of this region
in Bak function. Bak half-life was decreased by truncating the C-
segment (but not the whole C-terminus) presumably because an
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contrast, Bax lacking the C-segment was stable (data not shown),
perhaps due to a strong TM:groove interaction. TM-driven
degradation is not likely to contribute to turnover of wild-type Bak,
as the TM domain is normally membrane-inserted. In relation to
Bak conformation, truncating the whole C-terminus (BakDCT)
encouraged unfolding of the N-terminus, as a portion of the
protein failed to form a C14:C166 crosslink (Figure 1E) [8], and
exposure of N-terminal epitopes could be detected (data not
shown). Others have reported N-terminal epitope exposure in Bax
after truncation of the C-terminal 21 residues [30], although this
effect must be indirect as the N- and C-termini are not in contact
in the Bax structure [38].
Bak regulation is independent of mitochondrial
localization
Conversion of Bak to a semi-cytosolic protein (i.e. Bak/BaxCS)
did not alter its regulation by other Bcl-2 proteins. We were able to
test this in cells where Noxa-Mcl-1 signalling preferentially initiates
Bak-mediated rather than Bax-mediated apoptosis. In that system,
Bak/BaxCS responded like Bak rather than like Bax. In addition,
a mitochondrial Bax protein (S184L) responded like Bax rather
than like Bak. Thus, differences in the regulation of Bak and Bax
[24,25] are best explained by specific binding of Bak and Bax with
other Bcl-2 proteins such as Mcl-1, with this binding being largely
unaffected by initial subcellular localization.
Conclusions
The C-termini are important for Bak and Bax stability in the
cytosol and mitochondrial OM, for their translocation and insertion
into the OM, and for their conformation change and oligomeriza-
tion to finally form the apoptotic pore. Central to these functions is
conversion from a TM:groove to a TM:membrane conformation
either before apoptosis (Bak), or during apoptosis (Bax, Bak/
BaxCS). The conversion is dependent not only by residues within
the TM domain and the groove, but by residues within the C-
segment. Further studies are needed to confirm whether, during
apoptosis, converting from a TM:groove to a TM:membrane
conformation is triggered by TM dislodgement from the groove by
BH3-only proteins, post-translational modification, or changes to
the intracellular environment [7,27,38,47,51].
Materials and Methods
Ethics Statement
We used approximately 20 week old wild type or bak
2/2
C57BL-6 mice for this study. All animal care and experimental
procedures were conducted according to the guidelines of the
Australian Code of Practive for the Care and Use of Animals for
Scientific Purposes, 7
th Edition 2004, and the WEHI Animal
Ethics Committee, and were approved by the Royal Melbourne
Hospital Animal Ethics Committee (Approval #2009.012).
Cell culture, retroviral infection, induction of cell death,
apoptosis assays
Mouseembryonicfibroblasts (MEFs) derived from bak
2/2bax
2/2
mice were generated and transformed with SV40 large T as
described [23]. MEFs were maintained in Dulbecco’s Modified
Eagles medium supplemented with 10% fetal calf serum, 250 mM
L-asparagine and 55 mM 2-mercaptoethanol.
Variants of human Bak and Bax were generated by site-directed
mutagenesis (primer sequences available on request). Variants
were then stably expressed in bak
2/2bax
2/2 MEFs by retroviral
infection of pMX-IG (IRES-GFP) retroviral constructs that were
first introduced into Phoenix cells by FuGENE 6-mediated
transfection according to the manufacturer’s protocol (Roche).
Viral supernatants were then used to infect MEFs as previously
described [46]. Polyclonal populations of Bak- and Bax-expressing
cells (GFP-positive) were selected by FACSorting. For stable
expression of FLAG-Bak, FLAG-Bak/BaxCS or FLAG-Bcl-xL,
constructs were cloned into a pMIH (IRES-Hygro) retroviral
vector and polyclonal populations of infected cells selected by
serial passage in hygromycin.
To induce apoptosis, cells were treated with apoptotic stimuli
(100 J/m
2 UV; 1 mM actinomycin D (ActD); 10 mM etoposide;
50 mg/ml cycloheximide) and incubated at 37uC for 24 h, unless
indicated otherwise. Where indicated, cells were also co-incubated
in the presence of the broad range caspase inhibitor Q-VD.oph
(50 mM, Enzyme Systems, CA). To measure cell death, floating
cells were combined with trypsin-detached cells, resuspended in
phosphate-buffered saline containing 5 mg/ml propidium iodide,
and incubated on ice for 5 min before measuring the percentage
non-viable cells (propidium iodide positive) by flow cytometry.
Where indicated, the cell death data was analyzed by two-tailed
Student’s t-test.
Bak stability after protein synthesis inhibition
To estimate protein half-life, bak
2/2bax
2/2 cells expressing Bak
and Bax mutants were treated with cycloheximide (50 mg/ml). At
the indicated time points cells were harvested, and cell lysate
immunoblotted for Bak (Cat #B5929, Sigma), Bax (N20, Santa
Cruz Biotechnologies), or for b-actin (Sigma) as a loading control.
Bak subcellular localization and membrane insertion
To assess the subcellular localization of each Bak variant, MEFs
were harvested, washed in ice-cold PBS, and the cell membrane
permeabilized by resuspending cells at 1610
7 cells ml
21 in
permeabilization buffer (20 mM HEPES/KOH pH 7.5, 100 mM
sucrose, 2.5 mM MgCl2, 100 mM KCl, 1 mM DTT, 0.025%
digitonin, Complete protease inhibitors (Roche), and in most cases
4 mg/ml pepstatin A (Sigma)). After incubation on ice for 10 min,
cell membrane permeabilization was verified by uptake of trypan
blue, the cells centrifuged at 13,000 g for 5 min and equivalent
amounts of cytosol (Cyt) and membrane (Memb) fractions
immunoblotted for Bak, HSP70 as a cytosolic marker (HSP70
antibody is a gift from Dr W. Welch and Dr R. Anderson).
To assess membrane insertion of Bak, membrane fractions were
resuspended in 0.1 M Na2CO3 (pH 11.5) and incubated on ice for
20 min. pH was neutralized with 0.1 M HCl and incubated for
5 min before addition of 106nuclease buffer (400 mM Tris HCl,
100 mM MgSO4, 10 mM CaCl2) and 1 unit of DNAase I
(Promega), and incubation at 37uC for 10 min. Samples were
centrifuged at 13,000 g for 10 min and supernatant and pellet
fractions immunoblotted for Bak.
Detection of Bak conformation by disulphide bond
formation
MEFs were permeabilized by 0.025% digitonin in cross-linking
buffer (20 mM HEPES/KOH pH 7.5, 100 mM sucrose, 2.5 mM
MgCl2, 50 mM KCl), and membranes resuspended in the same
buffer without digitonin. For disulphide bond formation, cytosol
and membrane fractions were incubated with the redox catalyst
copper(II)(1,10-phenanthroline)3 (CuPhe) on ice for 30 min. The
CuPhe stock was 30 mM CuSO4 and 100 mM 1,10-phenanthro-
line in 4:1 water/ethanol and diluted 100-fold into the sample.
Oxidizing conditions were quenched by 20 mM EDTA to chelate
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residues, and the samples analyzed by non-reducing SDS-PAGE.
Isolation of mouse liver mitochondria
Mouse liver mitochondria (MLM) were isolated from approx-
imately 20-week old C57Bl-6 wild type or bak
2/2 mice as
previously described [41]. MLM were resuspended at 0.5 mg/ml
in MEF cytosolic extracts and incubated with or without caspase-
8-cleaved Bid (tBid) for 60 min at 37uC.
Mitochondrial outer membrane permeabilization by tBid
Permeabilized cells, or combinations of membrane and cytosol
fractions generated as above, were incubated with tBid for 30 or
60 min at 30uC. Where indicated, cytosol derived from MEFs was
incubated with MLM and incubated with tBid as above.
Supernatant and membrane fractions were separated by centri-
fugation (13,000 g for 5 min) and fractions transferred to
nitrocellulose for immunoblotting for cytochrome c, or to PVDF
for immunoblotting for Bak.
IASD labelling
Cytosoland membranefractions were separated and treated with
1 mM IASD (4-acetamido-49-((iodoacetyl) amino) stilbene-2,29-
disulfonic acid, Invitrogen) in the presence of 0.1 mM TCEP
(Tris(2-Carboxyethyl)phosphine; Pierce) for 30 mins at room
temperature. Labelling was quenched with 1 mM dithiothreitol
and labelling assessed by SDS-PAGE and immunoblotting for Bak.
Preferential Bak activation by Noxa overexpression
bak
2/2bax
2/2 MEFs expressing Bak, Bax, Bak/BaxCS or Bax
S184L were retrovirally infected with BimS or BimS containing the
BH3 domain from Bad or Noxa (provided by D.C.S. Huang, and
described in [46]). After 36 hours, cell death was assessed by
propidium iodide uptake. Percentage cell death was calculated by
normalizing against the rate of infection (GFP-positive cells) of the
three BimS constructs for bak
2/2bax
2/2 cells.
Supporting Information
Figure S1 Mitochondrial cytochrome c release mediat-
ed by Bak variants. bak
2/2bax
2/2 MEFs expressing the
indicated Bak variants were left untreated (black line) or treated
with UV (red lines) as in Figures 1B, 2B and 3B and examined for
mitochondrial cytochrome c (Cyt c) content by flow cytometry
(Waterhouse and Trapani, Cell Death Differ 2003 Jul; 10 (7): 853–
855) using anti-cytochrome c antibody (6H2.B4; Pharmingen) and
R-phycoerythrin-conjugated secondary antibody (1031-09; South-
ern Biotech, AL, USA). Untreated cells were incubated with
secondary antibody only (hatched). Cells with low mitochondrial
cytochrome c content lie to the left of the marker line. Results are
representative of two independent experiments.
(TIF)
Figure S2 Cell death mediated by Bak/BaxCS is apo-
ptotic. (A) Cell death mediated by Bak/BaxCS is blocked by
caspase inhibition. bak
2/2bax
2/2 MEFs expressing either wild-type
Bak or Bak/BaxCS were treated or not with etoposide (10 mM) in
the presence or absence of caspase inhibitor Q-VD.oph (50 mM) for
24 h prior to assessment of cell death by propidium iodide uptake.
Results are expressed as mean +/2 SEM of three independent
experiments. (B) Cell death mediated by Bak/BaxCS involves
cytochrome c release. bak
2/2bax
2/2 expressing Bak/BaxCS treated
as in (A) were harvested, and cytosolic (Cyt) and membrane (Memb)
fractions immunoblotted for cytochrome c, or for VDAC1 (31HL;
Calbiochem) as a mitochondrial membrane marker. Results are
representative of two independent experiments.
(TIF)
Figure S3 Bak/BaxCS oligomerizes predominantly in
the membrane fraction during apoptosis. bak
2/2bax
2/2
MEFs expressing Bak/BaxCS were treated with actinomycin D
(1 mM) in the presence of caspase-inhibitor Q-VD.oph (50 mM) for
24 h. Cells were fractionated into cytosol (Cyt) and membrane
(Memb) fractions prior to addition of oxidant (CuPhe) to induce
disulphide bonds. Samples were electrophoresed under non-
reducing (upper) or reducing (bottom) conditions prior to immuno-
blotting for Bak and for HSP70 as a cytosolic marker. MX, non-
activated intramolecular cross-linked monomer; M, non-cross-
linked monomer; D, intermolecular crosslinked dimers. Results are
representative of two independent experiments.
(TIF)
Figure S4 A variant of Bak/BaxCS containing an extra
tryptophan residue also retains full pro-apoptotic func-
tion. (A) C-terminalsequenceofBakand Baxvariants,inparticular
demonstrating the two Bak/BaxCS variants containing either four
(KKMG) or five (WKKMG) residues from Bax. (B) Both Bak/
BaxCS variants retain proapoptotic function. bak
2/2bax
2/2 MEFs
expressing Bak, Bak/BaxCS or Bak/BaxCS
b were left untreated or
treated with increasing doses of etoposide. Percentage cell death is
expressed as the mean 6 SEM from three independent experi-
ments. Statistical significance for the 10 mM dose when compared
to Bak is shown; *p,0.05. Panels on the right are cell lysates
immunoblotted for Bak, and for HSP70 as a loading control.
(TIF)
Figure S5 Bak/BaxCS redistributes to mitochondria
during apoptosis. (A) FLAG-tagged Bak/BaxCS is predomi-
nantly cytosolic. Cytosol (Cyt) and membrane (Memb) fractions
were generated from bak
2/2bax
2/2 MEFs stably expressing
FLAG-Bak or FLAG-Bak/BaxCS and immunoblotted for FLAG.
* is a non-specific band. (B) FLAG-Bak/BaxCS translocates to
mitochondria following etoposide treatment. FLAG-Bak or
FLAG-Bak/BaxCS expressing cells were left untreated or treated
with etoposide (10 mM) in the presence of Q-VD.oph (50 mM) for
24 h, and fixed in 4% paraformaldehyde for 20 mins at room
temperature. Following staining with an anti-FLAG primary
antibody (M2; Sigma) and FITC-conjugated secondary antibody
(Southern Biotech, AL, USA), immunofluorescence was detected
by confocal microscopy (Leica SP2). All images were obtained
using the same parameter settings. Bar represents 20 mm. Note
that staining with secondary antibody alone gave essentially no
signal (not shown). Images were from a single experiment,
representative of two experiments. (C) FLAG-Bak/BaxCS colo-
calizes with mitochondria. Cells were treated as in (B), except that
cells were incubated with with MitoTracker Deep Red FM
(0.5 mM; Invitrogen, CA) for 30 mins at 37uC prior to fixation and
immunostaining. Bar represents 20 mm. Images were from a single
experiment, representative of two experiments.
(TIF)
Figure S6 Cysteine variants of Bax and of Bak/BaxCS
retain proapoptotic function. bak
2/2bax
2/2 MEFs expressing
the indicated cysteine variants were left untreated or treated with
etoposide. Percentage cell death is expressed as the mean 6 SEM
from three independent experiments. Statistical significance for the
10 mM dose when compared to wild-type (wt) protein is shown;
*p,0.05. Panels on the right are cell lysates immunoblotted for Bax
or Bak, and re-blotted for HSP70 as a loading control.
(TIF)
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ited by Bcl-xL. (A) FLAG-Bcl-xL was stably expressed in bak
2/
2bax
2/2 MEFs expressing Bak/BaxCS. Cell lysates were
immunblotted for FLAG or Bak. (B) Bcl-xL is particularly efficient
at blocking Noxa-induced death. bak
2/2bax
2/2 MEFs expressing
Bak/BaxCS with or without FLAG-Bcl-xL were retrovirally
infected with BimS, or with BimS containing the Noxa or Bad
BH3 domains. Percentage cell death was assessed after 36 h by
propidium iodide uptake. Data is mean +/2 SEM of two
experiments. Statistical significance for the effect of Bcl-xL is
shown; *p,0.05.
(TIF)
Figure S8 Bak/BaxCS is regulated like Bak rather than
like Bax. bak
2/2bax
2/2 MEFs stably expressing Bak, Bak/
BaxCS or Bax (as in Figure 6) were treated with etoposide
(10 mM), UV (100 J/m
2), cycloheximide (CHX, 50 mg/ml) or
actinomycin D (ActD, 1 mM) for 24 h. Percentage cell death is
expressed as the mean 6 SEM from two independent experi-
ments. Statistical significance for each variant compared to Bak is
shown; *p,0.05.
(TIF)
Figure S9 Mcl-1 binds both Bak and Bak/BaxCS
strongly compared to its binding of Bax and BaxS184L.
bak
2/2bax
2/2 MEFs stably expressing the indicated Bak or Bax
variants, were also transfected with pMIH (IRES-Hygro) retroviral
vector expressing FLAG-Bcl-xL or FLAG-Mcl-1. After selection by
serial passage in hygromycin, polyclonal populations were lysed
with 1% Triton X-100 prior to immunoprecipitation with anti-
FLAG affinity resin (Sigma). Immunoprecipitated samples and cell
lysates were then immunoblotted for FLAG, Bak or Bax. Results
are representative of two independent experiments.
(TIF)
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